Clinical Trial Update: Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial investigating temozolomide plus carboplatin for recurrent glioblastoma multiforme has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Temodar (Temozolomide)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: WITHDRAWN